Cutler Group LP Kodiak Sciences Inc. Call Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 04, 2022	SELL	$5.04 - $9.48 $86,184 - $162,108	-17,100 Reduced 82.61%	3,600 $1,000
Q1 2022 Apr 14, 2022	BUY	$7.09 - $89.45 $146,763 - $1.85 Million	20,700 New	20,700 $8,000
Q4 2021 Jan 18, 2022	SELL	$80.85 - $128.49 $169,785 - $269,829	-2,100 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$81.97 - $106.94 $57,379 - $74,858	700 Added 50.0%	2,100 $11,000
Q2 2021 Jul 19, 2021	SELL	$77.2 - $126.54 $108,080 - $177,156	-1,400 Reduced 50.0%	1,400 $6,000
Q1 2021 Apr 26, 2021	SELL	$110.45 - $164.47 $1.08 Million - $1.61 Million	-9,800 Reduced 77.78%	2,800 $18,000
Q4 2020 Jan 21, 2021	BUY	$60.78 - $154.03 $522,708 - $1.32 Million	8,600 Added 215.0%	12,600 $284,000
Q3 2020 Oct 27, 2020	SELL	$45.05 - $59.27 $274,805 - $361,547	-6,100 Reduced 60.4%	4,000 $39,000
Q1 2020 May 07, 2020	BUY	$38.18 - $73.95 $190,900 - $369,750	5,000 Added 98.04%	10,100 $27,000
Q4 2019 Feb 06, 2020	BUY	$13.9 - $76.65 $70,890 - $390,915	5,100 New	5,100 $32,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $288M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.